

Relapsed/refractory classical Hodgkin lymphoma effectively treated



ALL

IMAGES

VIDEOS

14,200 Results

Any time ▾

**[PDF] Relapsed or refractory classical Hodgkin lymphoma: ...**[https://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045\(21\)00138-8.pdf](https://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(21)00138-8.pdf)

relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting. Br J Haematol. 2017; 179: 471–79. 7 Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the...

**Therapeutic Updates for Relapsed and Refractory Classical ...**<https://www.mdpi.com/2072-6694/12/10/2887/htm> ▾

Hodgkin lymphoma (HL) is a B-cell malignancy representing approximately one in ten lymphomas diagnosed in the United States annually. The majority of patients with HL can be cured with...

Cited by: 1

Author: Timothy J Voorhees, Anne W Beaven

Publish Year: 2020

## PEOPLE ALSO ASK

Is there a cure for Hodgkin's lymphoma? ▾

How is sintilimab used to treat classical Hodgkin lymphoma? ▾

When was radiation therapy first used to treat Hodgkin ' s lymphoma? ▾

What are the current advances in Hodgkin ' s lymphoma? ▾

Feedback

**Optimizing outcomes in relapsed/refractory Hodgkin ...**<https://journals.sagepub.com/doi/full/10.1177/2040620720902911>

Feb 16, 2020 · Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy. Br J Haematol...

Cited by: 1

Author: Theodoros P Vassilakopoulos, John V As...

Publish Year: 2020

**(PDF) Optimizing outcomes in relapsed/refractory Hodgkin ...**<https://www.researchgate.net/publication/339308707...>

The outcome of patients with relapsed/refractory classical Hodgkin lymphoma (rr-CHL) has improved

12,800 Results Any time ▾

**Therapeutic Updates for Relapsed and Refractory Classical ...**<https://www.mdpi.com/2072-6694/12/10/2887/htm>

Hodgkin lymphoma (HL) is a B-cell malignancy representing approximately one in ten lymphomas diagnosed in the United States annually. The majority of patients with HL can be cured with...

Cited by: 2

Author: Timothy J Voorhees, Anne W Beaven

Publish Year: 2020

**(PDF) Optimizing outcomes in relapsed/refractory Hodgkin ...**<https://www.researchgate.net/publication/339308707...>

The outcome of patients with relapsed/refractory classical Hodgkin lymphoma (rr-cHL) has improved considerably in recent years owing to the approval of highly active novel agents such as ...

**Optimizing outcomes in relapsed/refractory Hodgkin ...**<https://journals.sagepub.com/doi/10.1177/2040620720902911>

Feb 16, 2020 · Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy. Br J Haematol...

Cited by: 3

Author: Theodoros P Vassilakopoulos, John V Asi...

Publish Year: 2020

**Improved clinical outcome in a randomized phase II study ...**<https://europepmc.org/article/PMC/PMC8025784>

Apr 01, 2021 · Programmed death-1 (PD-1) blockade therapy has been approved and recommended for both the treatment of patients with classical Hodgkin lymphoma (cHL) who have relapsed or progresse...

**Addition of Low-Dose Decitabine to Anti-PD-1 Antibody ...**<https://www.researchgate.net/publication/332769821...>

(43) A combination of DAC plus anti-PD-1 camrelizumab gave a better complete remission rate than camrelizumab alone in patients with relapsed/refractory Hodgkin's lymphoma. (44) Low-dose DAC ...

**[PDF] Improved outcomes of high-risk relapsed Hodgkin lymphoma ...**<https://haematologica.org/article/download/haematol.2021.278311/73353>

Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a ...



国内版 国际版

Relapsed/refractory classical Hodgkin lymphoma effectively treated



ALL IMAGES VIDEOS

14,000 Results

Any time ▾

### Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in ...

<https://clincancerres.aacrjournals.org/content/27/10/2782> ▾

Purpose: Programmed death-1 (PD-1) blockade monotherapy is effective in relapsed/refractory classical Hodgkin lymphoma (cHL), but a subset of patients is recalcitrant to PD-1 inhibitors and onl...

### Therapeutic Updates for Relapsed and Refractory Classical ...

<https://www.mdpi.com/2072-6694/12/10/2887/htm> ▾

The approach to relapsed and refractory classical Hodgkin lymphoma is rapidly evolving. Over the past five years, we have seen the arrival of novel immunotherapies with impressive clinical response rat...

Cited by: 2

Author: Timothy J Voorhees, Anne W Beaven

Publish Year: 2020

Estimated Reading Time: 8 mins

### Optimizing outcomes in relapsed/refractory Hodgkin ...

<https://journals.sagepub.com/doi/full/10.1177/2040620720902911>

Feb 16, 2020 · The outcome of patients with relapsed/refractory classical Hodgkin lymphoma (rr-cHL) has improved considerably in recent years owing to the approval of highly active novel agents suc...

Cited by: 3

Author: Theodoros P Vassilakopoulos, John V As...

Publish Year: 2020

Estimated Reading Time: 4 mins

### Improved clinical outcome in a randomized phase II study ...

<https://europepmc.org/article/PMC/PMC8025784> ▾

Apr 01, 2021 · Thus, decitabine-plus-camrelizumab combination may be an extremely effective regimen for patients with relapsed/refractory cHL who progressed/relapsed after ASCT, especially if...

### (PDF) Improved clinical outcome in a randomized phase II ...

<https://www.researchgate.net/publication/350645191>...

Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma April 2021 Journal for ImmunoTherapy of Cancer 9(4):e002347

### Addition of Low-Dose Decitabine to Anti-PD-1 Antibody ...

<https://www.researchgate.net/publication/332769821>...

(43) A combination of DAC plus anti-PD-1 camrelizumab gave a better complete remission rate than